BioWorld

June 17, 2008

Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial

Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today) Read More

Mpex, GSK in Antibiotics Deal Using Efflux Pump Inhibitors

'Circuit Neuromics' Championed as Path to Understanding Mood

Want a Wicked Cool Hat? Try the BioWorld Booth

Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer

Other News To Note

EHA Roundup

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...